CareDx Rated Hold as Strong Near-Term Growth Offsets Reimbursement Headwinds and Naveris Acquisition Uncertainty

H.C. Wainwright analyst Yi Chen has reiterated their neutral stance on CDNA stock, giving a Hold rating yesterday.

Yi Chen has given his Hold rating due to a combination of factors tied to CareDx’s solid near‑term execution but balanced by unresolved longer‑term risks. The company delivered strong first‑quarter growth, lifted its 2026 revenue outlook, and is guiding to expanding testing volumes and improved profitability, yet management also highlighted reimbursement headwinds that are expected to weigh on revenue later in the year.

At the same time, the planned sale of the Lab Products unit and redeployment of proceeds into the acquisition of Naveris introduces both strategic upside and integration uncertainty. While Naveris adds a differentiated, faster‑growing oncology diagnostics platform that diversifies beyond transplant testing, the transaction is not yet closed, its contribution is excluded from current guidance, and execution around this pivot must still be proven, leading Chen to maintain a neutral stance on the shares.

In another report released yesterday, William Blair also maintained a Hold rating on the stock with a $21.91 price target.